West, N., Hemmings, G., Richman, S., Taylor, M., Chambers, P., Magill, L., Lancaster, D., Taniere, P., Handley, K., Brown, G., Ferry, D., Seymour, M., Gray, R., Morton, D., Warren, B., & Quirke, P. (2016). KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial. 226, S4–S4.

West, N., et al. KRAS and BRAF Mutational Status Can Be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT Trial. 2016, pp. S4–S4.

West, N, G Hemmings, S Richman, M Taylor, P Chambers, L Magill, D Lancaster, et al. 2016. “KRAS and BRAF Mutational Status Can Be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT Trial.” In , 226:S4–S4.